You are here

Our science / Clinical Trials / Find a Trial / NCT00174447

Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

Back to Search Print Save as PDF Bookmark Trial

NCT00174447

Last updated on February 17, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Avignon, , 84000 France
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who successfully completed study A1281031 (CGI score of 1 or 2 at final
visit) or ZIP-NY-98035 and with QTc

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- All other patients who do not fit the inclusion criteria as stated above.

NCT00174447
Pfizer
Completed
Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Schizophrenia
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
NCT00418171
All Genders
18+
Years
Multiple Sites
Schizophrenia
Safety, PK and PD Study in Healthy Male Japanese Subjects
NCT00447941
Males
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCT00645229
All Genders
18+
Years
Lisboa,
Schizophrenia
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
NCT00366704
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now